THE CAMBRIDGE DECLARATION:
Towards Clinical Trials for Drug-Resistant Tuberculosis
Cambridge, Massachusetts, USA
June 12, 2008

Because

- today millions of people are living with drug-resistant tuberculosis (TB),
- drug-resistant TB, which is transmissible and deadly, represents a public-health emergency,
- universal access to effective TB treatment is unachievable with current tools,
- inadequate treatment of drug-resistant TB leads to the emergence of extensively drug-resistant (XDR) TB, and
- there are huge gaps in our understanding of how to best treat drug-resistant TB,

we express extreme concern that the best available treatments are of limited efficacy and are reaching only a small fraction of people who need them. The others are left to die, with no or inadequate treatment.

On June 10-12, 2008, stakeholders from communities, NGOs, governments, donors, industry, and academia met in Cambridge, Massachusetts, USA, and declared the formation of a movement that will:

- conduct priority clinical trials that test strategies in adults and children:
  - to shorten and improve treatment for drug-resistant TB, and
  - to prevent drug-resistant TB
• mobilize the resources needed for these trials
• build the capacity of trial sites
• report to stakeholders on progress made, and
• ensure that these efforts complement those of other groups, and address the critical unmet needs outlined above.

For more information or to join protocol-writing groups, please contact: drtbworkshop@gmail.com.
SIGNATORIES, 2 July 2008

1. Ms. Paula Akugizibwe, AIDS and Rights Alliance for Southern Africa, Namibia
2. Dr. Elijah Amooti, African Eye Trust, England
3. Mr. Sidney Atwood, Brigham and Women's Hospital, USA
4. Dr. Renuka Babu, Medicine in Need, USA
5. Dr. Jaime Bayona, Socios En Salud-Sucursal Peru, Peru
6. Dr. Mercedes Becerra, Harvard Medical School, USA
7. Dr. Nulda Beyers, Desmond Tutu TB Centre, South Africa
8. Dr. Cesar Bonilla, National Health Strategy for TB Prevention and Control, Peru
9. Dr. Maryline Bonnet, Epicentre / Médecins Sans Frontières, Switzerland
10. Dr. William Burman, Denver Public Health, USA
11. Dr. Jose A. Caminero, International Union against Tuberculosis and Lung Disease, France
12. Dr. Peter Cegielski, U.S. Centers for Disease Control and Prevention, USA
13. Dr. Richard Chaisson, Johns Hopkins University School of Medicine, USA
14. Dr. Frank Cobelens, KNCV Tuberculosis Foundation, The Netherlands
15. Dr. Theodore Cohen, Brigham and Women's Hospital, USA
16. Dr. Margareth Dalcolmo, Helio Fraga Reference Center - FIOCRUZ / MoH, Brazil
17. Dr. Charles Daley, National Jewish Medical and Research Center, USA
18. Dr. Manfred Danilovits, Tartu University Lung Clinic, National Tuberculosis Program, Estonia
19. Dr. Anne Donnelly, Project Inform, USA
20. Mr. Karel De Beule, Tibotec, Belgium
21. Dr. Victor De Gruttola, Harvard School of Public Health, USA
22. Dr. Mary Ann DeGroote, Colorado State University, USA
23. Dr. Tine De Marez, Tibotec, Inc., USA
24. Dr. Ashwin Dharmadhikari, Brigham & Women's Hospital, USA
25. Ms. Nancy Dianis, Westat, USA
26. Dr. Anne Donnelly, Project Inform, USA
27. Dr. Kelly Dooley, Johns Hopkins University School of Medicine, USA
28. Dr. Kathleen Eisenach, University of Arkansas for Medical Sciences, USA
29. Dr. Gerald Friedland, Yale University School of Medicine, USA
30. Dr. Robert Gerety, Medicine in Need, USA
31. Dr. Ann Ginsberg, Global Alliance for TB Drug Development, USA
32. Dr. Howard Grossman, Fenway Community Health, USA
33. Dr. Abdul Hamid Salim, Damien Foundation, Bangladesh
34. Mr. Mark Harrington, Treatment Action Group, USA
35. Dr. Martin Hirsch, Harvard Medical School, USA
36. Dr. Timothy Holtz, U.S. Centers for Disease Control and Prevention, USA
37. Dr. Robert Horsburgh, Boston University School of Public Health, USA
38. Dr. Gary Horwith, Sequella, Inc., USA
39. Dr. Frauke Jochims, Médecins Sans Frontières, Switzerland
40. Dr. Salmaan Keshavjee, Harvard Medical School, USA
41. Dr. Michael Kimerling, University of Alabama at Birmingham School of Medicine, USA
42. Dr. Serena Koenig, Brigham and Women's Hospital, USA
43. Dr. Kitty Lambregts, KNCV Tuberculosis Foundation, The Netherlands, and MDR-TB Working Group of the Stop TB Partnership, Switzerland
44. Dr. Vaira Leimane, State Centre of Tuberculosis and Lung Diseases, Latvia
45. Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Disease, France
46. Dr. Pushpa Malla, National Tuberculosis Centre, National Tuberculosis Program, Nepal
47. Dr. William Mac Kenzie, U.S. Centers for Disease Control and Prevention, USA
48. Dr. Helen McIlreron, University of Cape Town, South Africa
49. Dr. Charles Mgone, European and Developing Countries Clinical Trials Partnership, Netherlands
50. Dr. Fuad Mirzayev, World Health Organization, Switzerland
51. Prof. Denis Mitchison, St. George's Hospital, UK
52. Dr. Carole Mitnick, Harvard Medical School, USA
53. Dr. Edward Nardell, Brigham and Women’s Hospital, USA
54. Dr. Eric Nuermberger, Johns Hopkins University School of Medicine, USA
55. Mrs. Carol Nyirenda, Treatment Advocacy and Literacy Campaign, Zambia
56. Dr. Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership, South Africa
57. Ms. Lesley Odendal, Treatment Action Campaign, South Africa
58. Dr. Charles Peloquin, National Jewish Medical and Research Center, USA
59. Dr. Sergey Popov, Moscow Medical Academy, Russia
60. Dr. Alexander Pym, Medical Research Council of South Africa, South Africa
61. Dr. Lee Reichman, University of Medicine and Dentistry of New Jersey, USA
62. Dr. Hind Satti, Partners In Health, Lesotho
63. Dr. Rajeswari Ramachandran, Tuberculosis Research Centre, India
64. Dr. Francisco Rosas, Vivir. Participación, Incidencia, y Transparencia, A.C., Mexico
65. Dr. Leonard Sacks, U.S. Food and Drug Administration, USA
66. Dr. Jussi Saukkonen, Boston University School of Medicine, USA
67. Dr. Neil Schluger, Columbia University Medical Center, USA
68. Dr. Kwonjune Seung, Brigham and Women’s Hospital, USA
69. Dr. Alexander Sloutsky, Massachusetts State Laboratory Institute, USA
70. Dr. Thelma Tupasi, Tropical Disease Foundation, Philippines
71. Dr. Frank van Leth, KNCV Tuberculosis Foundation, The Netherlands
72. Mr. Wim Vandevelde, European AIDS Treatment Group, Belgium
73. Dr. Francis Varaine, Médecins Sans Frontières, France
74. Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention, USA
75. Dr. Tido von Schoen-Angerer, Médecins Sans Frontières, Switzerland
76. Dr. Diana Weil, World Health Organization, Switzerland
77. Dr. Charles Wells, Otsuka America Pharmaceutical, Inc., USA
78. Dr. Matteo Zignol, World Health Organization, Switzerland
The workshop was convened by partners of the MDR-TB Working Group of the Stop-TB Partnership. It was sponsored and organized by: Boston University School of Public Health, International Union Against TB & Lung Disease, KNCV Tuberculosis Foundation, MDR-TB Working Group of the Stop-TB Partnership, Médecins Sans Frontières, Partners In Health/Harvard Medical School, Potts Memorial Foundation, Treatment Action Group, World Health Organization.